Skip to main content
Go to the home page of the European Commission (opens in new window)
English English
CORDIS - EU research results
CORDIS

Final development and commercial preparation of Phactory™, a universal platform technology to enable scalable phagebased drug development and production

Objective

The rise of drug-resistant bacteria necessitates the development of alternative therapies that can specifically target and eliminate these pathogens while minimizing harm to the patient's microbiome. Bacteriophages (phages) are potent therapeutics that can fight multidrugresistant pathogenic bacteria. Unlike broad-spectrum antibiotics, phages can selectively eliminate bacteria. However, the current production processes for phages pose considerable biosafety concerns and are often relatively inefficient, unreliable, and unscalable. Invitris has fundamentally transformed the way phages can be developed with its unique in vitro platform technology, Phactory™. For the first time, Phactory™ enables scalable, personalized production and rapid engineering of novel drugs based on phages. We aim to leverage the support by EIC to standardize the clinical production process of Phactory™ and conduct clinical trials to validate the efficacy and safety of novel phage-based therapies.

Fields of science (EuroSciVoc)

CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.

You need to log in or register to use this function

Coordinator

INVITRIS
Net EU contribution
€ 2 499 999,00
Address
AM KLOPFERSPITZ 19
82152 Planegg-Martinsried
Germany

See on map

SME

The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Yes
Region
Bayern Oberbayern München, Landkreis
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
No data
My booklet 0 0